Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
BMC Cancer
; 21(1): 1354, 2021 Dec 27.
Article
in English
| MEDLINE | ID: covidwho-1632816
ABSTRACT
BACKGROUND:
Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021.RESULTS:
Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.CONCLUSIONS:
Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunization Schedule
/
COVID-19
/
BNT162 Vaccine
/
2019-nCoV Vaccine mRNA-1273
/
Antibodies, Viral
/
Multiple Myeloma
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
BMC Cancer
Journal subject:
Neoplasms
Year:
2021
Document Type:
Article
Affiliation country:
S12885-021-09097-5
Similar
MEDLINE
...
LILACS
LIS